Takumi Futo¹, Ryo Uozaki², Takashi Yamaguchi³, Tomofumi Yamamoto¹, Hiroki Tsuji¹, Koichi Samata¹, Daiju Ichikawa¹, Maiko Matsushita¹, Yutaka Hattori¹ (1.Graduate School of Pharmaceutical Sciences, Keio Univ., Tokyo, Japan, 2.Daiichi Sankyo Co., Ltd., Tyuo-ku, Tokyo, Japan, 3.Novarthis Pharma K.K., Minato-ku, Tokyo, Japan)

Yawara Kawano¹, Takayuki Sasano², Yuki Inada², Nao Nishimura¹, Saki Kushima², Hiroyuki Hata², Masao Matsuoka¹ (1.Dept of Hematology, Kumamoto Univ Hospital, Kumamoto, Japan, 2.Faculty of Medical Sciences, Kumamoto University, Kumamoto, Japan)

Miho Arai, Sayaka Kajikawa, Kotaro Arita, Akinori Wada, Jun Murakami, Tsutomu Sato (Hematol., Toyama Univ., Toyama, Japan)

Mitsuhito Hirano¹, Yoichi Imai², Takahiko Murayama³, Kota Sato⁴, Junichi Yamamoto⁵, Muneyoshi Futami^1,2, Masaki Ri^6,7, Takumi Ito⁵, Hiroshi Yasui^2,8, Noriko Gotoh³, Shinsuke Iida⁶, Hiroshi Handa⁵, Arinobu Tojo^1,2 (1.Division of Molecular Therapy, IMSUT, 2.Department of Hematology/Oncology, IMSUT Hospital, 3.Division of Cancer Cell Biology Cancer Research Institute of Kanazawa University, 4.Department of Hematology, Japanese Red Cross Medical Center, 5.Department of Nanoparticle Translational Research, Tokyo Medical University, 6.Department of Hematology & Oncology, Nagoya City University, 7.Department of Blood Transfusion, Nagoya City University Hospital, 8.Fundamental Study on Cutting Edge of Genome Medicine, IMSUT)

Mohamed Rizk¹, Ola Rizq², Motohiko Oshima¹, Yaeko Nakajima-Takagi¹, Atsunori Saraya³, Yusuke Isshiki⁴, Atsushi Iwama¹, Naoya Mimura⁵ (1.Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan, 2.Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA, Boston, Boston, United States of America, 3.Department of Cellular and Molecular Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan, Chiba, Chiba, Japan, 4.Department of Hematology, Oami Municipal Hospital, Chiba, Japan, Chiba, Chiba, Japan, 5.Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan, Chiba, Chiba, Japan)

Yurie Nagai¹, Naoya Mimura^1,2, Ola Rizq³, Yusuke Isshiki¹, Motohiko Oshima⁴, Atsunori Saraya⁵, Mohamed Rizk⁴, Yaeko Nakajima⁴, Nagisa Oshima¹, Shokichi Tsukamoto¹, Shio Mitsukawa^1,2, Yusuke Takeda¹, Masahiro Takeuchi¹, Chikako Ohwada¹, Tohru Iseki^1,2, Chiaki Nakaseko^1,6, Atsushi Iwama⁴, Emiko Sakaida¹ (1.Department of Hematology, Chiba University Hospital, 2.Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 3.Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA, 4.Stem Cell and Molecular Medicine, IMS, The University of Tokyo, 5.Department of Cellular and Molecular Medicine, Chiba University Graduate School, 6.Department of Hematology, International University of Health and Welfare School)